- Home
- DYN vs ARQT Comparison
DYN vs ARQT Comparison
Compare DYN & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DYN | ARQT |
|---|---|---|
| Founded | 1984 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.2B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DYN | ARQT |
|---|---|---|
| Price | $18.85 | $25.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 8 |
| Target Price | $34.33 | ★ $39.63 |
| AVG Volume (30 Days) | 2.4M | ★ 2.5M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | N/A | ★ 0.09 |
| Revenue | N/A | ★ $376,072,000.00 |
| Revenue This Year | N/A | $44.19 |
| Revenue Next Year | N/A | $29.31 |
| P/E Ratio | ★ N/A | $284.11 |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $14.00 | $19.30 |
| 52 Week High | $27.31 | $34.80 |
Technical Indicators
Market Signals| Indicator | DYN | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 60.97 | 39.14 |
| Support Level | $16.65 | $23.42 |
| Resistance Level | $19.46 | $28.54 |
| Average True Range (ATR) | 0.90 | 1.46 |
| MACD | 0.40 | -0.81 |
| Stochastic Oscillator | 93.76 | 9.61 |
Price Performance
Historical ComparisonAbout DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.